Clinical Trial Detail

NCT ID NCT01586195
Title Study Of Zelboraf (Vemurafenib) in Patients With Locally-Advanced, Unresectable, Stage IIIc Or Metastatic Melanoma and Activating Exon 15 BRAF Mutations Other Than V600E
Recruitment Terminated
Gender both
Phase Phase II
Variant Requirements Yes
Sponsors Genentech
Indications

melanoma

Therapies

Vemurafenib

Age Groups: adult

Additional content available in CKB BOOST